Table 2.
Characteristics of study CHCs’ patients with diabetes as of May 30, 2014 (beginning of pre-intervention period)
| Arm 1 CHCs | Arm 2 CHCs | Arm 3 CHCs | Comparison CHCs | p value | |||||
|---|---|---|---|---|---|---|---|---|---|
| N | (%) | N | (%) | N | (%) | N | (%) | ||
| Total patients | 3849 | 5098 | 3370 | 33,638 | |||||
| Indicated for statin use | 3299 | (85.7) | 4239 | (83.2) | 2850 | (84.6) | 28,257 | (84.0) | 0.009 |
| Indicated for ACE/ARB use | 2589 | (67.3) | 3580 | (70.2) | 2369 | (70.3) | 22,808 | (67.8) | < 0.001 |
| Age (years) | 0.009 | ||||||||
| 18–21 | 31 | (0.8) | 33 | (0.6) | 24 | (0.7) | 212 | (0.6) | |
| 22 to 39 | 357 | (9.3) | 574 | (11.3) | 337 | (10.0) | 3649 | (10.8) | |
| 40 to 75 | 3169 | (82.3) | 4064 | (79.7) | 2744 | (81.4) | 27,309 | (81.2) | |
| > 75 | 292 | (7.6) | 427 | (8.4) | 265 | (7.9) | 2468 | (7.3) | |
| Gender | < 0.001 | ||||||||
| Female | 2047 | (53.2) | 3057 | (60.0) | 1831 | (54.3) | 18,707 | (55.6) | |
| Male | 1802 | (46.8) | 2041 | (40.0) | 1539 | (45.7) | 14,931 | (44.4) | |
| Race/ethnicity | < 0.001 | ||||||||
| Non-Hispanic White | 2,417 | (62.8) | 880 | (17.3) | 2389 | (70.9) | 15,582 | (46.3) | |
| Non-Hispanic Black | 44 | (1.1) | 1364 | (26.8) | 196 | (5.8) | 7056 | (21.0) | |
| Non-Hispanic Other | 127 | (3.3) | 350 | (6.9) | 126 | (3.7) | 2134 | (6.3) | |
| Hispanic | 1249 | (32.4) | 2494 | (48.9) | 652 | (19.3) | 8734 | (26.0) | |
| Unknown | 12 | (0.3) | 10 | (0.2) | 7 | (0.2) | 132 | (0.4) | |
| Patient preferred language | < 0.001 | ||||||||
| English | 2781 | (72.3) | 3259 | (63.9) | 2883 | (85.5) | 23,979 | (71.3) | |
| Spanish | 993 | (25.8) | 1690 | (33.2) | 395 | (11.7) | 7011 | (20.8) | |
| Other | 46 | (1.2) | 138 | (2.7) | 79 | (2.3) | 2372 | (7.1) | |
| Unknown | 29 | (0.8) | 11 | (0.2) | 13 | (0.4) | 276 | (0.8) | |
| Household income as % of FPL* | < 0.001 | ||||||||
| 0 to 100% | 1829 | (47.5) | 1456 | (28.6) | 1317 | (39.1) | 17,999 | (53.5) | |
| 101 to 200% | 776 | (20.2) | 425 | (8.3) | 758 | (22.5) | 6393 | (19.0) | |
| > 200% | 122 | (3.2) | 62 | (1.2) | 287 | (8.5) | 2271 | (6.8) | |
| Unknown | 1122 | (29.2) | 3155 | (61.9) | 1008 | (29.9) | 6975 | (20.7) | |
| Insurance status* | < 0.001 | ||||||||
| Medicaid | 1421 | (36.9) | 1924 | (37.7) | 1089 | (32.3) | 11,436 | (34.0) | |
| Medicare | 1403 | (36.5) | 1725 | (33.8) | 1315 | (39.0) | 10,386 | (30.9) | |
| Other public | 41 | (1.1) | 8 | (0.2) | 23 | (0.7) | 742 | (2.2) | |
| Private | 397 | (10.3) | 400 | (7.8) | 504 | (15.0) | 3829 | (11.4) | |
| Uninsured | 587 | (15.3) | 1041 | (20.4) | 439 | (13.0) | 7245 | (21.5) | |
| LDL control (mg/dL)** | < 0.001 | ||||||||
| Not in control (> 129 mg/dL) | 512 | (13.3) | 733 | (14.4) | 482 | (14.3) | 5311 | (15.8) | |
| In control (< = 129 mg/dL) | 2643 | (68.7) | 3453 | (67.7) | 2373 | (70.4) | 22,888 | (68.0) | |
| Unknown | 694 | (18.0) | 912 | (17.9) | 515 | (15.3) | 5439 | (16.2) | |
| HbA1c control (%)** | < 0.001 | ||||||||
| Not in control (> = 7) | 2022 | (52.5) | 2547 | (50.0) | 1735 | (51.5) | 17,265 | (51.3) | |
| In control (< 7) | 1561 | (40.6) | 2020 | (39.6) | 1428 | (42.4) | 14,186 | (42.2) | |
| Unknown | 266 | (6.9) | 531 | (10.4) | 207 | (6.1) | 2187 | (6.5) | |
| Blood pressure control (mm Hg)** | < 0.001 | ||||||||
| Not in control | 910 | (23.6) | 1,174 | (23.0) | 702 | (20.8) | 8258 | (24.5) | |
| In control (< 140/90:< 60 yo, < 150/90:> = 60 yo) | 2939 | (76.4) | 3923 | (77.0) | 2668 | (79.2) | 25,355 | (75.4) | |
| Unknown | - | - | 1 | (0.0) | - | - | 25 | (0.1) | |
*Assessed at most recent office visit prior to snapshot date **Most recent record available prior to snapshot date. P values from chi-square test for general association
ACE/ARB angiotensin-converting-enzyme inhibitor/Angiotensin II receptor blockers, CHC community health center, FPL Federal Poverty Level, HbA1c Hemoglobin A1c, LDL Low-density lipoprotein